92 related articles for article (PubMed ID: 26376801)
41. Baicalein increases the expression and reciprocal interplay of RUNX3 and FOXO3a through crosstalk of AMPKα and MEK/ERK1/2 signaling pathways in human non-small cell lung cancer cells.
Zheng F; Wu J; Zhao S; Luo Q; Tang Q; Yang L; Li L; Wu W; Hann SS
J Exp Clin Cancer Res; 2015 May; 34(1):41. PubMed ID: 25948105
[TBL] [Abstract][Full Text] [Related]
42. 8‑bromo‑7‑methoxychrysin induces apoptosis by regulating Akt/FOXO3a pathway in cisplatin‑sensitive and resistant ovarian cancer cells.
Ding Q; Chen Y; Zhang Q; Guo Y; Huang Z; Dai L; Cao S
Mol Med Rep; 2015 Oct; 12(4):5100-8. PubMed ID: 26151347
[TBL] [Abstract][Full Text] [Related]
43. Transcription factor FOXO3a mediates apoptosis in HIV-1-infected macrophages.
Cui M; Huang Y; Zhao Y; Zheng J
J Immunol; 2008 Jan; 180(2):898-906. PubMed ID: 18178829
[TBL] [Abstract][Full Text] [Related]
44. Regulation of p38, PKC/Foxo3a/p73 signaling network by GTP during erythroid differentiation in chronic myelogenous leukemia.
Meshkini A; Yazdanparast R
Cell Biochem Biophys; 2013 Nov; 67(2):675-87. PubMed ID: 23494264
[TBL] [Abstract][Full Text] [Related]
45. 18β-glycyrrhetinic acid induces apoptosis through modulation of Akt/FOXO3a/Bim pathway in human breast cancer MCF-7 cells.
Sharma G; Kar S; Palit S; Das PK
J Cell Physiol; 2012 May; 227(5):1923-31. PubMed ID: 21732363
[TBL] [Abstract][Full Text] [Related]
46. Induction of Mxi1-SR alpha by FOXO3a contributes to repression of Myc-dependent gene expression.
Delpuech O; Griffiths B; East P; Essafi A; Lam EW; Burgering B; Downward J; Schulze A
Mol Cell Biol; 2007 Jul; 27(13):4917-30. PubMed ID: 17452451
[TBL] [Abstract][Full Text] [Related]
47. The CtBP1-p300-FOXO3a transcriptional complex represses the expression of the apoptotic regulators Bax and Bim in human osteosarcoma cells.
Li C; Xiao XQ; Qian YH; Zhou ZY
J Cell Physiol; 2019 Dec; 234(12):22365-22377. PubMed ID: 31074088
[TBL] [Abstract][Full Text] [Related]
48. Insulin receptor substrate 2 and FoxO3a signalling are involved in E-cadherin expression and transforming growth factor-β1-induced repression in kidney epithelial cells.
Carew RM; Browne MB; Hickey FB; Brazil DP
FEBS J; 2011 Sep; 278(18):3370-80. PubMed ID: 21777391
[TBL] [Abstract][Full Text] [Related]
49. Involvement of miR17 pathway in glucocorticoid-induced cell death in pediatric acute lymphoblastic leukemia.
Harada M; Pokrovskaja-Tamm K; Söderhäll S; Heyman M; Grander D; Corcoran M
Leuk Lymphoma; 2012 Oct; 53(10):2041-50. PubMed ID: 22475310
[TBL] [Abstract][Full Text] [Related]
50. Crystal structure of the human FOXO3a-DBD/DNA complex suggests the effects of post-translational modification.
Tsai KL; Sun YJ; Huang CY; Yang JY; Hung MC; Hsiao CD
Nucleic Acids Res; 2007; 35(20):6984-94. PubMed ID: 17940099
[TBL] [Abstract][Full Text] [Related]
51. Foxo3a expression and acetylation regulate cancer cell growth and sensitivity to cisplatin.
Shiota M; Yokomizo A; Kashiwagi E; Tada Y; Inokuchi J; Tatsugami K; Kuroiwa K; Uchiumi T; Seki N; Naito S
Cancer Sci; 2010 May; 101(5):1177-85. PubMed ID: 20210796
[TBL] [Abstract][Full Text] [Related]
52. Glucocorticoids paradoxically promote steroid resistance in B cell acute lymphoblastic leukemia through CXCR4/PLC signaling.
Abdoul-Azize S; Hami R; Riou G; Derambure C; Charbonnier C; Vannier JP; Guzman ML; Schneider P; Boyer O
Nat Commun; 2024 May; 15(1):4557. PubMed ID: 38811530
[TBL] [Abstract][Full Text] [Related]
53. Deciphering the role of forkhead transcription factors in cancer therapy.
Yang JY; Hung MC
Curr Drug Targets; 2011 Aug; 12(9):1284-90. PubMed ID: 21443462
[TBL] [Abstract][Full Text] [Related]
54. FOXO3a-interacting proteins' involvement in cancer: a review.
Dong Z; Guo Z; Li H; Han D; Xie W; Cui S; Zhang W; Huang S
Mol Biol Rep; 2024 Jan; 51(1):196. PubMed ID: 38270719
[TBL] [Abstract][Full Text] [Related]
55. Forkhead box K2 modulates epirubicin and paclitaxel sensitivity through FOXO3a in breast cancer.
Nestal de Moraes G; Khongkow P; Gong C; Yao S; Gomes AR; Ji Z; Kandola N; Delbue D; Man EP; Khoo US; Sharrocks AD; Lam EW
Oncogenesis; 2015 Sep; 4(9):e167. PubMed ID: 26344694
[TBL] [Abstract][Full Text] [Related]
56. PI3Kδ inhibition potentiates glucocorticoids in B-lymphoblastic leukemia by decreasing receptor phosphorylation and enhancing gene regulation.
Zimmerman JAO; Fang M; Pufall MA
bioRxiv; 2023 Aug; ():. PubMed ID: 36798391
[TBL] [Abstract][Full Text] [Related]
57. Overcoming adaptive resistance in AML by synergistically targeting FOXO3A-GNG7-mTOR axis with FOXO3A inhibitor Gardenoside and rapamycin.
Chen Z; Guo Q; Huang S; Li L; Wu F; Liu Z; Li Z; Chen T; Song G; Xu S; Chen J; Hou Y
Genes Dis; 2024 Jan; 11(1):397-412. PubMed ID: 37588187
[TBL] [Abstract][Full Text] [Related]
58. The Aurora kinase/β-catenin axis contributes to dexamethasone resistance in leukemia.
Shah K; Ahmed M; Kazi JU
NPJ Precis Oncol; 2021 Feb; 5(1):13. PubMed ID: 33597638
[TBL] [Abstract][Full Text] [Related]
59. Emerging Epigenetic and Posttranslational Mechanisms Controlling Resistance to Glucocorticoids in Acute Lymphoblastic Leukemia.
Borin C; Pieters T; Serafin V; Ntziachristos P
Hemasphere; 2023 Jul; 7(7):e916. PubMed ID: 37359189
[TBL] [Abstract][Full Text] [Related]
60. Small Molecule that Reverses Dexamethasone Resistance in T-cell Acute Lymphoblastic Leukemia (T-ALL).
Cantley AM; Welsch M; Ambesi-Impiombato A; Sanchez-Martin M; Kim MY; Bauer A; Ferrando A; Stockwell BR
ACS Med Chem Lett; 2014 Jul; 5(7):754-9. PubMed ID: 25050160
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
